Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Secret Agent Society: a Randomized Controlled Trial of a Transdiagnostic Youth Social Skills Group Treatment.
Temkin AB, Beaumont R, Wkya K, Hariton JR, Flye BL, Sheridan E, Miranda A, Vela J, Zendegui E, Schild J, Gasparro S, Loubriel D, Damiandies A, Weisman J, Silvestre A, Yadegar M, Catarozoli C, Bennett SM. Temkin AB, et al. Among authors: gasparro s. Res Child Adolesc Psychopathol. 2022 Jul;50(7):975. doi: 10.1007/s10802-022-00932-2. Res Child Adolesc Psychopathol. 2022. PMID: 35604478 No abstract available.
Secret Agent Society: A Randomized Controlled Trial of a Transdiagnostic Youth Social Skills Group Treatment.
Temkin AB, Beaumont R, Wkya K, Hariton JR, Flye BL, Sheridan E, Miranda A, Vela J, Zendegui E, Schild J, Gasparro S, Loubriel D, Damianides A, Weisman J, Silvestre A, Yadegar M, Catarozoli C, Bennett SM. Temkin AB, et al. Among authors: gasparro s. Res Child Adolesc Psychopathol. 2022 Sep;50(9):1107-1119. doi: 10.1007/s10802-022-00919-z. Epub 2022 Apr 20. Res Child Adolesc Psychopathol. 2022. PMID: 35441908 Clinical Trial.
Correction to: Secret Agent Society: A Randomized Controlled Trial of a Transdiagnostic Youth Social Skills Group Treatment.
Temkin AB, Beaumont R, Wkya K, Hariton JR, Flye BL, Sheridan E, Miranda A, Vela J, Zendegui E, Schild J, Gasparro S, Loubriel D, Damianides A, Weisman J, Silvestre A, Yadegar M, Catarozoli C, Bennett SM. Temkin AB, et al. Among authors: gasparro s. Res Child Adolesc Psychopathol. 2022 Oct;50(10):1247. doi: 10.1007/s10802-022-00955-9. Res Child Adolesc Psychopathol. 2022. PMID: 35796917 No abstract available.
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Vaccaro A, Cognetti F, Fabi A, Gasparro S, Garrone O, Alicicco MG, Urracci Y, Mansutti M, Poletti P, Correale P, Bighin C, Puglisi F, Montemurro F, Colantuoni G, Lambertini M, Boni L; Gruppo Italiano Mammella Investigators. Del Mastro L, et al. Among authors: gasparro s. Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10. Lancet Oncol. 2022. PMID: 36370716 Clinical Trial.
Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer.
Allegretti M, Fabi A, Giordani E, Ercolani C, Romania P, Nisticò C, Gasparro S, Barberi V, Ciolina M, Pescarmona E, Giannarelli D, Ciliberto G, Cognetti F, Giacomini P. Allegretti M, et al. Among authors: gasparro s. Mol Cancer. 2021 Nov 29;20(1):151. doi: 10.1186/s12943-021-01438-z. Mol Cancer. 2021. PMID: 34839818 Free PMC article. No abstract available.
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
Rossi V, Berchialla P, Giannarelli D, Nisticò C, Ferretti G, Gasparro S, Russillo M, Catania G, Vigna L, Mancusi RL, Bria E, Montemurro F, Cognetti F, Fabi A. Rossi V, et al. Among authors: gasparro s. Cancers (Basel). 2019 Oct 26;11(11):1661. doi: 10.3390/cancers11111661. Cancers (Basel). 2019. PMID: 31717791 Free PMC article.
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO).
Roila F, Fumi G, Ruggeri B, Antonuzzo A, Ripamonti C, Fatigoni S, Cavanna L, Gori S, Fabi A, Marzano N, Graiff C, De Sanctis V, Mirabile A, Serpentini S, Bocci C, Pino MS, Cilenti G, Verusio C, Ballatori E; NICSO (Network Italiano per le Cure di Supporto in Oncologia). Roila F, et al. Support Care Cancer. 2019 Mar;27(3):1041-1047. doi: 10.1007/s00520-018-4393-9. Epub 2018 Aug 6. Support Care Cancer. 2019. PMID: 30084104
17 results